Biocompatible flexible hemostatic sheet

A biocompatible flexible hemostatic sheet with reactive polymer particles addresses the challenge of controlling bleeding during surgical procedures by forming a gel seal and adhering to tissues, effectively minimizing blood loss and ensuring strong adhesion.

JP7589416B2Active Publication Date: 2024-11-26GATT TECH
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2021577001
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-01-14
Filing Date
2020-07-09
Publication Date
2024-11-26
Estimated Expiration
2040-07-09

AI Technical Summary

Technical Problem

Existing surgical techniques for controlling bleeding, such as suture control and electrocautery, are often insufficient during procedures on parenchymal tissues like the liver or kidney, necessitating the development of alternative hemostatic products that can effectively minimize blood loss.

Method used

A biocompatible, flexible hemostatic sheet comprising a water-resistant adhesive fibrous carrier structure with three-dimensional interconnected interstitial spaces and reactive polymer particles that covalently bond with tissues and blood proteins to induce hemostasis and tissue adhesion.

Benefits of technology

The hemostatic sheet rapidly forms a gel to seal wounds, providing strong adhesion and effective hemostasis, even on irregular surfaces, with minimal bending friction and mechanical strength, while being bioabsorbable and suitable for laparoscopic procedures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007589416000001
    Figure 0007589416000001
  • Figure 0007589416000002
    Figure 0007589416000002
  • Figure 0007589416000003
    Figure 0007589416000003
Patent Text Reader

Abstract

The present invention relates to a biocompatible, flexible hemostatic sheet comprising: a water-resistant, adhesive fibrous carrier structure comprising three-dimensional interconnected interstitial spaces, the fibrous carrier structure comprising fibers containing a nucleophilic polymer carrying reactive nucleophilic groups; and a plurality of reactive polymer particles distributed within the interstitial spaces, the reactive polymer particles comprising a water-soluble electrophilic polymer carrying at least three reactive electrophilic groups, the reactive electrophilic groups being capable of reacting with amine groups in tissue and blood and with the reactive nucleophilic groups of the nucleophilic polymer under the formation of covalent bonds, the reactive polymer particles having a diameter in the range of 0.5 to 100 pm and present in an amount of at least 3% by weight of the fibrous carrier structure.
Need to check novelty before this filing date? Find Prior Art

Description

Detailed Description of the Invention

[0001] [Technical field of the invention] The present invention relates to a biocompatible, flexible hemostatic sheet that can be suitably used to minimize blood loss during a surgical procedure. A water-resistant adhesive fibrous carrier structure comprising three-dimensional interconnected void spaces, the water-resistant adhesive fibrous carrier structure comprising fibers containing a nucleophilic polymer carrying reactive nucleophilic groups; and Reactive polymer particles comprising a water-soluble electrophilic polymer carrying at least three reactive electrophilic groups distributed within the interstitial spaces, said reactive electrophilic groups being capable of reacting with amine groups in tissues and blood and with reactive nucleophilic groups of a nucleophilic polymer under the formation of covalent bonds. Includes.

[0002] [Background of the invention] One of the main challenges during surgical procedures on parenchymal tissue is to achieve control of bleeding. Suture control, electrocautery and ultrasonic sealing are often inadequate, for example, during liver or kidney surgery. As a result, procedures such as liver resection or partial nephrectomy require alternative methods to control bleeding. To this end, a wide range of topical hemostatic products have been developed and are clinically available.

[0003] Lewis et al. (Control of bleeding in surgical procedures: critical appraisal of HEMOPATCH (Sealing Hemostat), Dove Press Journal: Medical Devices Evidence and Research, 22 December 2015, 1-9) describe a hemostatic pad (HEMOPATCH) composed of a synthetic protein-reactive monomer and a collagen backing. The active side is covered with a protein-reactive monomer: N-hydroxysuccinimide-functionalized polyethylene glycol (NHS-PEG). NHS-PEG allows rapid attachment of the collagen pad to tissue, promoting and maintaining hemostasis.

[0004] Schuhmacher et al. (Safety and effectiveness of a synthetic hemostatic patch for intraoperative soft tissue bleeding, Med Devices (Auckl). 2015;8:167-174) describe a hemostatic patch (Veriset™) composed of an absorbent backing, oxidized cellulose, and polyethylene glycol hydrogel. The Veriset™ hemostatic patch is provided as a ready-to-use patch with the polyethylene glycol side applied to the bleeding site.

[0005] Boerman et al. (Next Generation Hemostatic Materials Based on NHS-Ester Functionalized Poly(2-oxazoline)s, Biomacromolecules (2017), 18, 2529-2538) describe a synthetic, non-bioactive hemostatic product obtained by coating N-hydroxysuccinimide ester (NHS)-functionalized poly(2-oxazoline)s (NHS-POx) onto gelatin patches, which acts by forming covalent crosslinks between the polymer, host blood proteins, gelatin, and tissue to seal wound sites and prevent blood loss during surgical procedures.

[0006] US Patent Application Publication No. 2010 / 0233246 describes a biocompatible polymeric device comprising a collagen sponge or sheet impregnated with a two-component reactive polyethylene glycol powder, the reactive powder comprising a first polyethylene glycol having nucleophilic groups and a second polyethylene glycol having electrophilic groups, the polyethylene glycol powder remaining non-reactive in the dry state.

[0007] WO 2010 / 059280 describes an anhydrous fibrous sheet comprising a first component of a fibrous polymer containing electrophilic or nucleophilic groups and a second component capable of crosslinking with the first component to form a crosslinked hydrogel adherent to biological tissue when the sheet is exposed to an aqueous medium in contact with biological tissue; a) the second component is a fibrous polymer having the same or different backbone structure as the fibrous polymer of the first component, and containing electrophilic groups when the first component contains nucleophilic groups, or containing nucleophilic groups when the first component contains electrophilic groups; b) the second component is a coating on the fibrous polymer of the first component, said coating containing electrophilic groups if the first component contains nucleophilic groups, or containing nucleophilic groups if the first component contains electrophilic groups; or c) describes an anhydrous fibrous sheet in which the second component is a dry powder dispersed and entrapped within the interstices of the fibrous polymer of the first component, said powder containing electrophilic groups if the first component contains nucleophilic groups, or containing nucleophilic groups if the first component contains electrophilic groups.

[0008] US Patent Application Publication No. 2011 / 0250257 describes an anhydrous fibrous sheet comprising a first component of a fibrous polymer containing electrophilic or nucleophilic groups and a second component capable of crosslinking with the first component to form a crosslinked hydrogel adherent to biological tissue when the sheet is exposed to an aqueous medium in contact with biological tissue, the second component being either a fibrous polymer containing electrophilic groups when the first component contains nucleophilic groups, or a fibrous polymer containing nucleophilic groups when the first component contains electrophilic groups, or a second component being capable of crosslinking with the first component to form a crosslinked hydrogel adherent to biological tissue when the sheet is exposed to an aqueous medium in contact with biological tissue, the second component being either a fibrous polymer containing electrophilic groups when the first component contains nucleophilic groups, or a fibrous polymer containing nucleophilic groups when the first component contains electrophilic groups, An anhydrous fibrous sheet is described in which the component is a coating on the fibrous polymer of a first component, said coating containing electrophilic groups if the first component contains nucleophilic groups, or containing nucleophilic groups if the first component contains electrophilic groups, or a second component is a dry powder dispersed and entrapped within the interstices of the fibrous polymer of the first component, said powder containing electrophilic groups if the first component contains nucleophilic groups, or containing nucleophilic groups if the first component contains electrophilic groups.

[0009] WO 2011 / 124640 is a) providing a sponge comprising a matrix of biomaterial in dry form; b) providing one reactive polymeric material in the form of a dry powder; c) contacting a) with b) such that the material of b) is present on at least one surface of the sponge; and d) A step of adhering the material of b) to the sponge of a). The present invention describes a method for making a hemostatic sponge, comprising: Adhesion can be achieved by melting for a sufficiently long period of time.

[0010] WO 2012 / 057628 describes a tissue-adhesive medical product comprising at least 1% by weight of dry matter of electrophilically activated polyoxazoline (EL-POx), said EL-POx comprising at least two reactive electrophilic groups, including at least one pendant electrophilic group. In addition to EL-POx, the medical product may also contain nucleophilically activated polyoxazoline (NU-POx). Examples of tissue-adhesive products include adhesive tissue tapes, tissue sealants, hemostatic porous materials and implants.

[0011] WO 2016 / 056901 describes an adhesive hemostatic product selected from a coated mesh, a coated foam or a coated powder, the hemostatic product comprising: a porous solid substrate having a porosity of at least 5 vol.% and comprising an exterior surface comprising a nucleophilic polymer containing reactive nucleophilic groups; and An adherent coating covering at least a portion of a solid substrate, said coating comprising an electrophilically activated polyoxazoline (EL-POx), said EL-POx containing an average of at least one reactive electrophilic group. This application describes an adhesive hemostatic product comprising: The adhesive hemostatic product is produced by a method that includes providing a porous solid substrate, coating the substrate with a coating solution that includes EL-POx and a solvent, and removing the solvent.

[0012] [Summary of the invention] The present inventors have developed a biocompatible, flexible hemostatic sheet that is particularly suitable for preventing blood loss during laparoscopic surgical procedures.

[0013] The hemostatic sheet according to the present invention comprises a water-resistant adhesive fibrous carrier structure that retains host blood proteins and tissues, as well as small particles comprising reactive electrophilic polymers that can covalently bond with reactive nucleophilic groups in the fibrous carrier structure, thereby inducing hemostasis and / or tissue adhesion. Thus, one aspect of the present invention is a biocompatible, flexible hemostatic sheet comprising: A water-resistant adhesive fibrous support structure comprising three-dimensional interconnected void spaces, said fibrous support structure comprising fibers containing a nucleophilic polymer carrying reactive nucleophilic groups; and A plurality of reactive polymer particles comprising a water-soluble electrophilic polymer carrying at least three reactive electrophilic groups distributed within the interstitial spaces, the reactive electrophilic groups being capable of reacting with amine groups in tissues and blood and reactive nucleophilic groups of a nucleophilic polymer under formation of covalent bonds, the reactive polymer particles having a diameter in the range of 0.5-100 μm and present in an amount of at least 3% by weight of the fibrous carrier structure. The present invention relates to a biocompatible, flexible hemostatic sheet comprising:

[0014] The hemostatic sheet of the present invention comprises a water-resistant, adhesive fibrous carrier structure that absorbs blood as soon as blood can penetrate into the interstitial spaces. This fibrous carrier structure can be easily impregnated with reactive polymer particles. Unlike impregnation with liquids, such dry impregnation does not affect the structural integrity or mechanical properties of the carrier structure. When blood is absorbed by the hemostatic sheet of the present invention, the reactive polymer particles in the sheet begin to dissolve as soon as they are "wet" by the blood, thereby allowing the electrophilic polymer to react with both the reactive nucleophilic groups in the blood and tissue and the reactive nucleophilic groups in the fibrous carrier structure, thereby inducing blood clotting and tissue sealing, both of which contribute to hemostasis.

[0015] Although the inventors do not wish to be bound by theory, it is believed that the advantageous properties of the hemostatic sheet of the present invention may be due to the fact that the reactive polymer particles are distributed throughout the fibrous carrier structure, which creates minimal bending friction, and that due to their small particle size, these reactive polymer particles dissolve quickly when they come into contact with blood or other aqueous body fluids. Thus, when the sheet is applied to the wound site, rapid covalent crosslinking occurs between the reactive electrophilic polymer on the one hand and blood proteins, tissue and the fibrous carrier structure on the other hand, thereby forming a gel, which can seal the wound surface to stop bleeding and also provide strong adhesion of the fibrous sheet to tissue. The water-resistant fibrous carrier structure provides mechanical strength during and after application and prevents excessive expansion.

[0016] Due to its flexibility, the hemostatic sheet of the present invention can be suitably applied to bleeding sites of irregular shapes. The hemostatic sheet may be applied in layers if the already applied sheet does not completely stop the bleeding.

[0017] Another aspect of the present invention is a method for preparing a hemostatic sheet, said method comprising: Providing a sheet of the water-resistant adhesive fibrous carrier structure defined above; Providing reactive polymer particles as defined above; and Distributing reactive polymer particles within the interstitial spaces of the fibrous support structure. The present invention relates to a method comprising the steps of:

[0018] [Detailed Description of the Invention] Thus, one aspect of the present invention is a biocompatible flexible hemostatic sheet comprising: A water-resistant adhesive fibrous support structure comprising three-dimensional interconnected void spaces, said fibrous support structure comprising fibers containing a nucleophilic polymer carrying reactive nucleophilic groups; and A plurality of reactive polymer particles comprising a water-soluble electrophilic polymer carrying at least three reactive electrophilic groups distributed within the interstitial spaces, the reactive electrophilic groups being capable of reacting with amine groups in tissues and blood and reactive nucleophilic groups of a nucleophilic polymer under formation of covalent bonds, the reactive polymer particles having a diameter in the range of 0.5-100 μm and present in an amount of at least 3% by weight of the fibrous carrier structure. The present invention relates to a biocompatible, flexible hemostatic sheet comprising:

[0019] The term "hemostatic sheet" as used herein, unless otherwise indicated, refers to a sheet capable of stopping bleeding from damaged tissue. The hemostatic sheets of the present invention may achieve hemostasis by turning blood into a gel and / or forming a seal to close the wound site.

[0020] As used herein, the term "tissue adhesive" refers to the ability of the hemostatic sheet to adhere to tissue through the formation of covalent bonds between the sheet and the tissue. The formation of these covalent bonds typically requires the presence of water.

[0021] The term "water-resistant" as used herein in relation to a fibrous carrier structure means that the structure is not water-soluble and does not disintegrate or form a colloidal dispersion in water at neutral pH conditions (pH 7) and a temperature of 37°C.

[0022] The term "interstitial space" as used herein refers to void ("empty") space within the fibrous support structure. The interstitial space within the fibrous support structure allows for the introduction of reactive polymer particles into the structure. Blood and other bodily fluids can also enter the interstitial space, thereby allowing dissolution of the water-soluble electrophilic polymer within the reactive polymer particles.

[0023] The concentration of reactive polymer particles having a diameter in the range of 0.5 to 100 μm is expressed as weight % of the fibrous support structure itself, ie excluding the reactive polymer particles.

[0024] The "water-soluble electrophilic polymer carrying reactive electrophilic groups" used according to the present invention carries at least three reactive groups capable of reacting with amine groups in tissues and blood under the formation of covalent bonds. The water-soluble electrophilic polymer has a molecular weight of at least 1 kDa and a solubility in distilled water at 20° C. of at least 50 g / L.

[0025] The term "water absorbency" as used herein is a measure of the ability of a hemostatic sheet to absorb water. Water absorbency is measured by weighing a sample of the dry sheet (weight = W d ), and then the sample is immersed in distilled water (37°C) for 45 minutes. The sample is then removed from the water, and the water adhering to the outside of the substrate is removed, after which the sample is weighed again (weight = W w ). Water absorption capacity=100%×(W w -W d ) / W d Water absorption capacity is a measure of the porosity of a substrate and its ability to swell in the presence of water.

[0026] The term "collagen" as used herein refers to the major structural protein in the extracellular space of various connective tissues in the animal body. Collagen forms a characteristic triple helix of three polypeptide chains. Depending on the degree of mineralization, collagen tissues can be either strong (bone) or flexible (tendon) or have a gradient from strong to flexible (cartilage). Unless otherwise indicated, the term "collagen" also includes denatured collagens other than gelatin.

[0027] The term "gelatin" as used herein refers to a mixture of peptides and proteins produced by partial hydrolysis of collagen extracted from the skin, bones and connective tissues of animals such as domestic cattle, chickens, pigs and fish. During hydrolysis, the natural molecular bonds between the individual collagen strands are broken down into forms that are more easily reconstituted.

[0028] The term "polyoxazoline" as used herein refers to poly(N-acylalkyleneimine) or poly(aroylalkyleneimine), further referred to as POx. An example of POx is poly(2-ethyl-2-oxazoline). The term "polyoxazoline" also encompasses copolymers of POx.

[0029] The reactive polymer particles may be homogeneously distributed in the interstitial space of the fibrous carrier structure, in the sense that the particle density is substantially the same throughout the carrier structure. The reactive polymer particles may also be non-uniformly distributed throughout the carrier structure. For example, when a hemostatic sheet is prepared in the form of a laminate of a thin layer of a fibrous carrier structure and a layer of reactive polymer particles, the density of the reactive polymer particles within the sheet may vary. In certain applications, it may be advantageous for the density of the reactive polymer particles to exhibit a gradient, for example, in that the density of the reactive particles is lowest near the side of the sheet that is intended to be applied to the bleeding wound and highest near the opposite side of the sheet.

[0030] The diameter distribution of reactive polymer particles may be determined by laser diffraction, preferably using a Malvern Mastersizer 2000 in combination with a Stainless Steel Sample Dispersion Unit. The sample dispersion unit is filled with approximately 120 ml of cyclohexane and the unit is allowed to stabilize for 5-10 minutes at a stirring speed of 1800 rpm, after which a background measurement (blank measurement) is taken. The sample tube is shaken and rotated horizontally 20 times. Approximately 50 mg is then dispersed in the sample dispersion unit containing cyclohexane. Once the sample is introduced into the dispersion unit, it is stirred at 1800 rpm for 1 minute 30 seconds to ensure that all particles are properly dispersed, after which measurements are taken. No sonication is performed on the dispersed particles. The average particle size is determined by D[4,3], the volume weighted average diameter (ΣniDi 4 ) / (ΣniDi 3 )

[0031] In particularly preferred embodiments, unlike the fibrous tissue sealants described in U.S. Patent Application Publication No. 2011 / 0250257, the hemostatic sheets of the present invention do not form hydrogels, i.e., water-swellable polymer matrices that can absorb substantial amounts of water and form elastic gels.

[0032] According to particularly preferred embodiments, the hemostatic sheets of the present invention are bioabsorbable, i.e., the carrier structure, reactive polymer particles, and any other components of the hemostatic sheet are ultimately absorbed by the body. Absorption of the carrier structure and reactive polymer particles typically requires chemical degradation (e.g., hydrolysis) of the polymers contained therein.

[0033] Complete bioabsorption of the hemostatic sheet by the human body is typically achieved in 1 to 10 weeks, preferably 2 to 8 weeks.

[0034] The hemostatic sheet of the present invention typically has an uncompressed average thickness of 0.5 to 25 mm, more preferably in the range of 1 to 10 mm, and most preferably in the range of 1.5 to 5 mm.

[0035] The dimensions of the hemostatic sheet are preferably at least 2 cm at the top and bottom of the sheet. 2 , more preferably at least 10 cm 2 , most preferably 25-50 cm 2 Typically the sheets are rectangular in shape, with a length of 25-200 mm and a width of 25-200 mm.

[0036] The hemostatic sheet is preferably 200 mg / cm 3 less than 150 mg / cm 3 less than 10-100 mg / cm 3 It has an uncompressed density of

[0037] In one embodiment of the invention, the reactive polymer particles are homogeneously distributed within the interstitial spaces of the fibrous carrier structure. In another embodiment of the invention, the hemostatic sheet is a laminate comprising alternating layers of fibrous carrier structure and layers of reactive polymer particles. In the latter embodiment, the reactive polymer particles are preferably contained within layers of the fibrous carrier structure that separate the layers of reactive polymer particles.

[0038] The hemostatic sheets of the present invention are preferably essentially anhydrous. Typically, the hemostatic sheets have a moisture content of 5 wt.% or less, more preferably 2 wt.% or less, and most preferably 1 wt.% or less.

[0039] The water absorption capacity of the hemostatic sheet is preferably at least 50%, more preferably in the range of 100% to 800%, and most preferably in the range of 200% to 500%.

[0040] The hemostatic sheets of the present invention are preferably sterile.

[0041] The reactive polymer particles in the hemostatic sheet preferably comprise a water-soluble electrophilic polymer bearing reactive electrophilic groups selected from carboxylate esters, sulfonate esters, phosphonate esters, pentafluorophenyl esters, p-nitrophenyl esters, p-nitrothiophenyl esters, acid halide groups, anhydrides, ketones, aldehydes, isocyanates, thioisocyanates, isocyano, epoxides, activated hydroxyl groups, olefins, glycidyl ethers, carboxyls, succinimidyl esters, sulfosuccinimidyl esters, maleimides (maleimidyl), ethenesulfonyl, imidoesters, acetoacetates, haloacetals, orthopyridyl disulfides, dihydroxyphenyl derivatives, vinyls, acrylates, acrylamides, iodoacetamides, and combinations thereof. More preferably, the reactive electrophilic group is selected from carboxylate esters, sulfonate esters, phosphonate esters, pentafluorophenyl esters, p-nitrophenyl esters, p-nitrothiophenyl esters, acid halide groups, anhyinidrides, ketones, aldehydes, isocyanates, thioisocyanates, isocyano, epoxides, activated hydroxyl groups, glycidyl ethers, carboxyls, succinimidyl esters, sulfosuccinimidyl esters, imido esters, dihydroxyphenyl derivatives, and combinations thereof. Even more preferably, the reactive electrophilic group is selected from haloacetals, orthopyridyl disulfides, maleimides, vinyl sulfones, dihydroxyphenyl derivatives, vinyls, acrylates, acrylamides, iodoacetamides, succinimidyl esters, and combinations thereof. Most preferably, the reactive electrophilic group is selected from maleimides, vinyls, acrylates, acrylamides, succinimidyl esters, sulfosuccinimidyl esters, and combinations thereof.

[0042] Examples of succinimidyl esters which may be utilized include succinimidyl glutarate, succinimidyl propionate, succinimidyl succinamide, succinimidyl carbonate, disuccinimidyl suberate, bis(sulfosuccinimidyl)suberate, dithiobis(succinimidyl propionate), bis(2-succinimidooxycarbonyloxy)ethyl sulfone, 3,3'-dithiobis(sulfosuccinimidyl-propionate), succinimidyl carbamate, sulfosuccinimidyl(4-iodoacetyl)acetate, and the like. sulfosuccinimidyl esters, ...

[0043] Examples of dihydroxyphenyl derivatives that may be utilized include dihydroxyphenylalanine, 3,4-dihydroxyphenylalanine (DOPA), dopamine, 3,4-dihydroxyhydroccinamic acid (DOHA), norepinephrine, epinephrine, and catechol.

[0044] The use of a fibrous carrier structure in the hemostatic sheet of the present invention offers the advantage that the reactive polymer particles can be distributed homogeneously throughout the carrier structure without difficulty, which is much more difficult to achieve with, for example, a foam carrier structure.

[0045] The fibers of the fibrous carrier structure preferably have an average diameter of 1 to 500 μm, more preferably 2 to 300 μm, most preferably 5 to 200 μm. The average diameter of the fibers can be suitably determined using a microscope.

[0046] Typically, at least 50 wt.%, more preferably at least 80 wt.%, of the fibers of the fibrous support structure have a diameter of from 1 to 300 μm and a length of at least 1 mm.

[0047] Preferably, at least 50 wt.%, more preferably at least 80 wt.%, of the fibers of the fibrous support structure have an aspect ratio (ratio of length to diameter) of at least 1000.

[0048] The fibrous carrier structure utilized by the present invention is preferably a felt, woven or knitted structure. Most preferably, the fibrous carrier structure is a felt structure, where the term "felt structure" refers to a structure produced by matting fibers and pressing them together to form a cohesive material.

[0049] According to certain preferred embodiments, the fibrous support structure is biodegradable.

[0050] The nucleophilic polymer contained in the fibrous carrier structure may be homogenously distributed throughout the fibers contained in the carrier structure or may be applied as an external coating layer. The presence of the nucleophilic polymer in the carrier structure improves both the adhesive and hemostatic properties of the hemostatic sheet.

[0051] Preferably, the fibers of the fibrous support structure contain at least 5 wt.%, more preferably at least 10 wt.%, more preferably at least 50 wt.% of the nucleophilic polymer. Most preferably, the fibers consist of said nucleophilic polymer.

[0052] The nucleophilic polymer contained in the fibers of the carrier structure typically contains at least 2 reactive nucleophilic groups, more preferably at least 5 reactive nucleophilic groups, even more preferably at least 10 reactive nucleophilic groups, and most preferably at least 20 reactive nucleophilic groups.

[0053] These reactive nucleophilic groups are preferably selected from amine groups, thiol groups, phosphine groups, and combinations thereof. More preferably, these reactive nucleophilic groups are selected from amine groups, thiol groups, and combinations thereof. Most preferably, the reactive nucleophilic groups are amine groups. These amine groups are preferably selected from primary amine groups, secondary amine groups, and combinations thereof.

[0054] The nucleophilic polymer in the fibers of the fibrous support structure preferably has a nitrogen content of at least 1 wt.%, more preferably 5-10 wt.%, most preferably 15-25 wt.%.

[0055] The nucleophilic polymer is preferably selected from proteins, chitosan, synthetic polymers carrying reactive nucleophilic groups, carbohydrate polymers carrying reactive nucleophilic groups and combinations thereof. More preferably, the nucleophilic polymer is selected from gelatin, collagen, chitosan and combinations thereof. Even more preferably, the nucleophilic polymer is gelatin, most preferably cross-linked gelatin.

[0056] Chitosan is a biodegradable, non-toxic complex carbohydrate derivative of chitin (poly-N-acetyl-D-glucosamine), a naturally occurring substance. Chitosan is the deacetylated form of chitin. The chitosan applied according to the present invention preferably has a degree of deacetylation higher than 70%.

[0057] The fibrous support structure preferably comprises at least 50 wt.%, more preferably at least 80 wt.%, and most preferably at least 90 wt.%, of fibers containing a nucleophilic polymer carrying reactive nucleophilic groups.

[0058] In a preferred embodiment, the fibrous support structure comprises at least 50 wt.%, more preferably at least 80 wt.%, and most preferably at least 90 wt.%, of fibers containing at least 50 wt.% of a nucleophilic polymer carrying reactive nucleophilic groups.

[0059] According to a particularly preferred embodiment, the fibrous carrier structure comprises at least 50 wt.%, more preferably at least 80 wt.%, most preferably at least 90 wt.% of fibres made from gelatin, collagen or chitosan.

[0060] Preferred collagens are devoid of telopeptide regions ("atelopeptide collagens"). The collagens utilized by the present invention are preferably selected from the group of synthetic human collagens, such as microfibrillar collagen, type I collagen, type III collagen, or a combination of types I and III collagen. Collagen crosslinked using heat, radiation, or chemical agents such as glutaraldehyde can also be used.

[0061] According to a preferred embodiment, the fibers in the fibrous carrier structure comprise at least 50 wt.%, more preferably at least 80 wt.%, most preferably at least 90 wt.% gelatin. The gelatin in the fibers preferably has a bloom strength of 200 or more.

[0062] In a particularly advantageous embodiment, the fibrous carrier structure comprises at least 50 wt.%, more preferably at least 80 wt.%, most preferably at least 90 wt.% partially cross-linked gelatin. The use of partially cross-linked gelatin offers the advantage that the fibrous carrier structure is sufficiently stable and flexible at body temperature, and furthermore the expansion of the fibrous carrier structure does not result in the formation of closed-pore fibrous gel structures.

[0063] In preparing the hemostatic sheet of the present invention, it may be advantageous to react some of the reactive electrophilic groups in the electrophilic polymer of the reactive polymer particles with the reactive nucleophilic groups of the nucleophilic polymer, so that the reactive polymer particles can be effectively fixed within the fibrous carrier structure.

[0064] According to a preferred embodiment, the reactive nucleophilic groups of the nucleophilic polymer in the fibers of the fibrous support structure comprise amine groups and the reactive electrophilic groups of the electrophilic polymer in the reactive polymer particles are selected from carboxylate esters, sulfonate esters, phosphonate esters, pentafluorophenyl esters, p-nitrophenyl esters, p-nitrothiophenyl esters, acid halide groups, anhydrides, ketones, aldehydes, isocyanates, thioisocyanates, isocyano, epoxides, activated hydroxyl groups, glycidyl ethers, carboxyls, succinimidyl esters, sulfosuccinimidyl esters, imido esters, dihydroxyphenyl derivatives and combinations thereof.

[0065] According to another preferred embodiment, the reactive nucleophilic group of the nucleophilic polymer comprises a thiol group, and the reactive electrophilic group of the electrophilic polymer in the reactive polymer particle is selected from haloacetals, orthopyridyl disulfides, maleimides, vinyl sulfones, dihydroxyphenyl derivatives, vinyls, acrylates, acrylamides, iodoacetamides, succinimidyl esters, sulfosuccinimidyl esters, and combinations thereof. More preferably, the reactive electrophilic group is selected from succinimidyl esters, sulfosuccinimidyl esters, haloacetals, maleimides or dihydroxyphenyl derivatives, and combinations thereof. Most preferably, the reactive electrophilic group is selected from maleimides or dihydroxyphenyl derivatives, and combinations thereof.

[0066] In a preferred embodiment of the invention, the fibrous support structure does not comprise oxidized regenerated cellulose.

[0067] Preferred fibrous support structures have an air permeability of at least 0.1 L / min×cm 2 , more preferably at least 0.5 L / min×cm 2 It has an open pore structure.

[0068] The air permeability is determined according to EN ISO 9237:1995 (Determination of the air permeability of textile fabrics).

[0069] The fibers in the fibrous carrier structure may be produced by methods known in the art, such as electrospinning, electroblown spinning, and high-speed rotary atomizer spinning. The production of fibrous carrier structures by high-speed rotary atomizer spinning is described in US Patent Application Publication No. 2015 / 0010612. Commercially available hemostatic fibrous sheets can also be used as the fibrous carrier structure. An example of a suitable commercially available product is GELITA TUFT-IT® (formerly Gelita Medical).

[0070] The reactive polymer particles are present in the hemostatic sheet of the present invention in an amount of preferably 5 to 90% by weight of the fibrous carrier structure, more preferably 10 to 80% by weight, even more preferably 20 to 75% by weight, and most preferably 50 to 70% by weight.

[0071] The reactive polymer particles preferably contain at least 10 wt.% water-soluble electrophilic polymer. More preferably, the reactive polymer particles contain at least 50 wt.%, more preferably at least 90 wt.% water-soluble electrophilic polymer.

[0072] The reactive polymer particles distributed within the interstitial spaces of the fibrous support structure preferably have a volume weighted average particle size in the range of 2 to 75 μm, more preferably in the range of 1 to 50 μm, most preferably in the range of 1 to 25 μm.

[0073] The reactive polymer particles of the present invention may be prepared in a variety of ways, such as by milling, by spray drying a polymer solution, by freeze drying, by spray cooling a polymer melt, by granulating a powder mixture, or by fluidized bed coating.

[0074] The water-soluble electrophilic polymers typically have a molecular weight of at least 2 kDa, more preferably at least 5 kDa, and most preferably between 10 and 100 kDa.

[0075] The water-soluble electrophilic polymer has a solubility in distilled water at 20° C. of at least 100 g / L, more preferably at least 200 g / L.

[0076] The water-soluble electrophilic polymers utilized by the present invention preferably contain at least 4 reactive electrophilic groups, more preferably at least 8 reactive electrophilic groups, even more preferably at least 16 reactive electrophilic groups, and most preferably at least 32 reactive electrophilic groups.

[0077] The water-soluble electrophilic polymer present in the reactive polymer particles is preferably selected from polyoxazoline, polyethylene glycol, polyvinylpyrrolidone, polyurethane (e.g., as described in WO 2017 / 171551), and combinations thereof. Even more preferably, the electrophilic polymer is selected from polyoxazoline, polyethylene glycol, and combinations thereof. Most preferably, the electrophilic polymer is polyoxazoline.

[0078] Polyoxazolines containing reactive electrophilic groups have repeating units of the following formula (I): (CHR 1 ) m NCOR 2 (In the formula, R 2 and R 1 each of which is H, optionally substituted C 1~22 alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl, and optionally substituted aryl, and m is 2 or 3. It is preferred that the polyoxazoline is derived from a polyoxazoline represented by the formula:

[0079] Preferably, R in formula (I) 1 and R 2 H and C 1~8 Alkyl, even more preferably H and C 1~4 R is selected from alkyl. 1 is most preferably H. The integer m in formula (I) is preferably equal to 2.

[0080] According to a preferred embodiment, the polyoxazoline is a polymer, even more preferably a homopolymer of 2-alkyl-2-oxazoline, said 2-alkyl-2-oxazoline being selected from 2-methyl-2-oxazoline, 2-ethyl-2-oxazoline, 2-propyl-2-oxazoline, 2-butyl-2-oxazoline and combinations thereof. Preferably, the polyoxazoline is a homopolymer of 2-propyl-2-oxazoline or 2-ethyl-oxazoline. Most preferably, the polyoxazoline is a homopolymer of 2-ethyl-oxazoline.

[0081] According to certain preferred embodiments, the water-soluble electrophilic polymer comprises at least 20 oxazoline units, more preferably at least 30 oxazoline units, and most preferably at least 80 oxazoline units. The electrophilic polymer preferably comprises an average of at least 0.05 reactive electrophilic groups per oxazoline residue. Even more preferably, the electrophilic polymer comprises an average of at least 0.1 reactive electrophilic groups per oxazoline residue. Most preferably, the electrophilic polymer comprises an average of 0.12 to 0.5 reactive electrophilic groups per oxazoline residue.

[0082] The water-soluble electrophilic polymer typically bears an average of at least 10, more preferably at least 20, reactive electrophilic groups.

[0083] The polyoxazoline may carry reactive electrophilic groups on its side chains (pendant reactive electrophilic groups), at its termini, or both.

[0084] The polyoxazolines utilized according to the present invention advantageously contain one or more pendant reactive electrophilic groups.Typically, the polyoxazolines contain from 0.03 to 0.5 pendant reactive electrophilic groups per monomer, more preferably from 0.04 to 0.35 pendant reactive electrophilic groups per monomer, and even more preferably from 0.05 to 0.25 pendant reactive electrophilic groups per monomer.

[0085] The polyethylene glycol (PEG) comprising reactive electrophilic groups applied according to the present invention is preferably a multi-arm PEG or star-shaped PEG comprising at least three arms, more preferably at least four arms, terminated with reactive electrophilic groups.

[0086] In addition to the water-soluble electrophilic polymer, the reactive polymer particles may contain a polysaccharide, preferably selected from dextran, alginate, oxidized cellulose (including oxidized regenerated cellulose (ORC)), hydroxyethyl cellulose, hydroxymethyl cellulose, hyaluronic acid, and combinations thereof. Preferably, such polysaccharides are contained in the reactive polymer particles at a concentration of at least 15 wt.%, more preferably at least 25 wt.%, and most preferably at least 50 wt.%. In certain preferred embodiments, the reactive polymer particles contain at least 25 wt.%, and most preferably at least 50 wt.% ORC.

[0087] In an advantageous embodiment of the present invention, besides the water-soluble electrophilic polymer, the reactive polymer particles additionally contain a nucleophilic crosslinker containing at least two reactive nucleophilic groups that can react with the reactive electrophilic groups of other water-soluble polymers under the formation of covalent bonds, and optionally one or more polysaccharides. The introduction of a nucleophilic crosslinker brings the advantage that when blood, or more importantly body fluids containing a relatively small amount of nucleophilic proteins (e.g., liver bile), enter the sheet, the water-soluble electrophilic polymer reacts with the nucleophilic crosslinker, which may improve the hemostatic and adhesive properties of the sheet. This crosslinking reaction leads to the formation of a hydrogel that fixes the flow of blood or body fluids, and this hydrogel sticks to tissue by forming covalent bonds between the reactive electrophilic groups in the hydrogel and the amine / thiol groups in the tissue. Combining the water-soluble electrophilic polymer and the nucleophilic crosslinker within a single particle ensures that these two reactive components can be homogeneously distributed throughout the hemostatic sheet, that separation will not occur during shipping and handling, and that the components can react with each other rapidly when the particle comes into contact with blood or aqueous body fluids.

[0088] Reactive polymer particles, i.e. reactive hybrid particles, containing a combination of a water-soluble polymer carrying a reactive electrophilic group and a nucleophilic crosslinker may be produced by wet granulation, preferably under reduced pressure, followed by drying. The granulation liquid should be selected so that little or no reaction occurs between the water-soluble electrophilic polymer and the nucleophilic crosslinker during granulation. This can be achieved, for example, by utilizing a granulation liquid in which at least one of these two components is insoluble. Most preferably, the water-soluble polymer carrying a reactive electrophilic group is insoluble in the granulation liquid.

[0089] According to a particularly preferred embodiment, the reactive polymer particles are particle agglomerates comprising (i) electrophilic particles containing a water-soluble electrophilic polymer, and (ii) nucleophilic particles containing a nucleophilic crosslinker.

[0090] The electrophilic particles preferably contain at least 30 wt.%, more preferably at least 50 wt.%, and most preferably at least 80 wt.% water-soluble electrophilic polymer.

[0091] The nucleophilic particles preferably contain at least 30 wt.%, more preferably at least 50 wt.%, and most preferably at least 80 wt.% nucleophilic crosslinker.

[0092] Typically, the reactive hybrid particles according to this embodiment have the following composition: (a) 50-95 wt. % of a water-soluble electrophilic polymer bearing at least three reactive electrophilic groups; (b) 5 to 50 wt.% of a nucleophilic crosslinker; (c) 0 to 50 wt.% polysaccharide wherein the combined combination of components (a)-(c) comprises at least 80 wt.%, more preferably at least 90 wt.% of the reactive polymer particles. According to a particularly preferred embodiment, the water-soluble electrophilic polymer carrying reactive electrophilic groups utilized in this embodiment is a polyoxazoline (EL-POx).

[0093] The reactive polymer particles preferably contain the water-soluble electrophilic polymer and the nucleophilic crosslinker in amounts such that the ratio between the total number of reactive electrophilic groups provided by the water-soluble electrophilic polymer and the total number of reactive nucleophilic groups provided by the nucleophilic crosslinker is in the range of 25:1 to 1:1, more preferably in the range of 18:1 to 2:1, and most preferably in the range of 12:1 to 2.5:1.

[0094] The nucleophilic crosslinking agent preferably contains at least 3 reactive nucleophilic groups, more preferably at least 5 reactive nucleophilic groups, even more preferably at least 10 reactive nucleophilic groups, and most preferably at least 20 reactive nucleophilic groups.

[0095] The reactive nucleophilic groups of the nucleophilic crosslinker are preferably selected from amine groups, thiol groups, phosphine groups and combinations thereof, more preferably selected from amine groups, thiol groups and combinations thereof. Most preferably, these reactive nucleophilic groups are amine groups. According to a preferred embodiment, the reactive nucleophilic groups present in the nucleophilic crosslinker are primary amine groups.

[0096] The nucleophilic crosslinker preferably has a nitrogen content of at least 1 wt.%, more preferably 5-10 wt.%, and most preferably 15-25 wt.%.

[0097] In one embodiment of the present invention, the nucleophilic crosslinker is a low molecular weight polyamine having a molecular weight of less than 1,000 g / mol, more preferably less than 700 g / mol, and most preferably less than 400 g / mol. Examples of suitable low molecular weight polyamines include dilysine, trilysine, tetralysine, pentalysine, dicysteine, tricysteine, tetracysteine, pentacysteine, oligopeptides containing two or more amino acid residues selected from lysine, ornithine, cysteine, arginine, and combinations thereof, as well as other amino acid residues, spermine, tris(aminomethyl)amine, arginine, and combinations thereof.

[0098] According to another embodiment of the invention, the nucleophilic crosslinker is a high molecular weight (>1,000 g / mol) polyamine selected from the group of nucleophilically activated POx (NU-POx); amine-functionalized polyethylene glycol, chitosan; chitosan derivatives (e.g., dicarboxy-derivatized chitosan polymers described in WO 2009 / 028965); polyethyleneimine; polyvinylamine; polyallylamine; amine-functionalized poly(meth)acrylates; saccharides containing amine functional moieties, such as aminoglycosides; polypeptides comprising two or more amino acid residues selected from lysine, ornithine, cysteine, arginine, and combinations thereof, and combinations thereof. Albumin, of natural origin or recombinant, is an example of a polypeptide that can be suitably utilized as the polypeptide. 4,6-disubstituted deoxystreptamines (kanamycin A, amikacin, tobramycin, dibekacin, gentamicin, sisomicin, netilmicin), 4,5-disubstituted deoxystreptamines (neomycin B, C and neomycin E (paromomycin)) and non-deoxystreptamine aminoglycosides such as streptomycin are examples of aminoglycosides that may be utilized. Most preferably, the high molecular weight polyamine is NU-POx.

[0099] In yet another embodiment of the present invention, the nucleophilic crosslinker utilized in the reactive polymer particles is a low molecular weight polythiol containing two or more thiol groups with a molecular weight of less than 1,000 g / mol, more preferably less than 700 g / mol, and most preferably less than 400 g / mol.Even more preferably, the nucleophilic crosslinker is selected from the group of trimercaptopropane, ethanedithiol, propanedithiol, 2-mercaptoethyl ether, 2,2'-(ethylenedioxy)diethanethiol, tetra(ethylene glycol)dithiol, penta(ethylene glycol)dithiol, hexaethylene glycoldithiol; thiol modified pentaerythritol, dipentaerythritol, trimethylolpropane or ditrimethylolpropane; oligopeptides containing at least two cysteine ​​units.

[0100] According to yet another embodiment of the present invention, the nucleophilic crosslinker utilized in the reactive polymer particles is a high molecular weight (>1,000 g / mol) polythiol selected from the group of NU-POx containing at least two thiol groups; thiol-functionalized poly(meth)acrylates; polysaccharides containing thiol functional moieties; polypeptides containing two or more thiol groups.

[0101] Preferably, the nucleophilic crosslinker is a high molecular weight polyamine selected from the group consisting of nucleophilically activated POx (NU-POx); amine-functionalized polyethylene glycol, chitosan; chitosan derivatives, polyethyleneimine; polyvinylamine; polyallylamine; amine-functionalized poly(meth)acrylate; saccharides containing amine functional moieties; polypeptides containing two or more amino acid residues selected from lysine, ornithine, cysteine, arginine, and combinations thereof, and combinations thereof. More preferably, the nucleophilic crosslinker is selected from NU-POx; amine-functionalized polyethylene glycol; gelatin, collagen, and combinations thereof. Most preferably, the high molecular weight polyamine is NU-POx.

[0102] The high molecular weight polyamine preferably contains 3 or more amine groups, more preferably 10 or more amine groups, and most preferably 20 or more amine groups.

[0103] In a particularly preferred embodiment of the present invention, the reactive polymer particles contain 50 to 95 wt.% EL-POx and 5 to 50 wt.% NU-POx, more preferably 60 to 90 wt.% EL-POx and 10 to 40 wt.% NU-POx, and most preferably 70 to 85 wt.% EL-POx and 15 to 30 wt.% NU-POx.

[0104] According to another advantageous embodiment, the reactive polymer particles contain a dry buffer system. Preferably, the buffer system has a buffer pH in the range of 7 to 11, more preferably in the range of 8 to 10.

[0105] Preferably, the buffer system has a concentration of at least 10 mmol.l -1.pH -1 More preferably, the buffer capacity is at least 25 mmol.l -1 .pH -1 and most preferably the buffer capacity is at least 50 mmol.l -1 .pH -1 It is.

[0106] The present inventors have unexpectedly discovered that hemostatic sheets having particularly desirable adhesive properties may be obtained by utilizing reactive polymer particles containing 1-20 wt.%, more preferably 2.5-15 wt.%, and most preferably 5-10 wt.% of a non-reactive non-ionic polymer, which does not contain reactive electrophilic or nucleophilic groups.

[0107] In a highly preferred embodiment, the reactive polymer particles are coated with a non-reactive non-ionic polymer.

[0108] The non-reactive nonionic polymer preferably has a melting point in the range of 40 to 70° C., more preferably in the range of 45 to 65° C., and most preferably in the range of 50 to 60° C. Here, the melting point refers to the temperature at which the polymer completely melts.

[0109] Examples of non-reactive non-ionic polymers suitable for use in the reactive polymer particles of the present invention include poloxamers, polyethylene glycols, and combinations thereof. Poloxamers are non-ionic triblock copolymers consisting of a central hydrophobic chain of polyoxypropylene (poly(propylene oxide)) flanked by two hydrophilic chains of polyoxyethylene (poly(ethylene oxide)), and are represented by the formula (I): [ka] (In the formula, a is an integer of 10 to 110, and b is an integer of 20 to 60.) When a is 80 and b is 27, the polymer is known as poloxamer 188. Other known poloxamers useful in the present invention are poloxamer 237 (a=64 and b=37), poloxamer 338 (a=141 and b=44), and poloxamer 407 (a=101 and b=56). Additional poloxamers that are known and may be useful in the present invention include poloxamer 108, poloxamer 182, poloxamer 183, poloxamer 212, poloxamer 217, poloxamer 238, poloxamer 288, poloxamer 331, poloxamer 338, and poloxamer 335.

[0110] According to a particularly preferred embodiment, the non-reactive non-ionic polymer is a poloxamer, even more preferably a poloxamer having an average molecular mass between 2000 and 18000, most preferably a poloxamer having an average molecular mass between 7000 and 10000. The poloxamer applied to the particle agglomerates is preferably solid at room temperature.

[0111] Another aspect of the present invention relates to a sealed package containing one or more hemostatic sheets according to the present invention.

[0112] Yet another aspect of the present invention is a method for preparing a hemostatic sheet, said method comprising: Providing a sheet of the water-resistant adhesive fibrous carrier structure defined above; Providing reactive polymer particles as defined above; and Distributing reactive polymer particles within the interstitial spaces of the fibrous support structure. The present invention relates to a method comprising the steps of:

[0113] The reactive polymer particles may be distributed in the interstitial spaces using dry or wet methods, with the dry method being preferred, in which the reactive polymer particles are applied in the form of a powder, and the powder is dispersed throughout the interstitial spaces in dry form.

[0114] According to one preferred embodiment of this dry process, the reactive polymer particles are distributed within the interstitial spaces of the fibrous support structure by shaking or vibrating a sheet of the fibrous support structure.

[0115] According to another embodiment of the dry method, the hemostatic sheet comprises: a) providing a sheet of a fibrous support structure; b) depositing a layer of reactive polymer particles onto a sheet of a fibrous support structure; c) superposing another sheet of fibrous support structure onto the layer of reactive polymer particles; and Optionally repeating steps b) and c) one or more times. The coating is prepared by a lamination method comprising:

[0116] Distribution of the reactive polymer particles within the laminate so obtained may be enhanced by shaking or vibrating the laminate.

[0117] In the wet method of distributing reactive polymer particles, a dispersion of reactive polymer particles in a low boiling organic liquid is used to impregnate the fibrous support structure, followed by evaporation of the low boiling organic liquid, preferably under reduced pressure. Typically, the low boiling organic liquid has a boiling point at atmospheric pressure of less than 150°C, more preferably less than 98°C, and most preferably less than 80°C.

[0118] Preferably, in the method of the present invention, the support structure containing the distributed reactive polymer particles is heated above the glass temperature of the water-soluble electrophilic polymer for at least 5 minutes. Heating the polymer particles in this manner causes the particles to become viscous and adhere to the fibrous support structure. Typically, the polymer particles are heated to a temperature of at least 40°C, more preferably 50-80°C, for at least 15 minutes.

[0119] Alternatively, the reactive polymer particles may be simply adhered to the fibrous support structure by exposing the fibrous support structure containing the distributed reactive polymer particles to a humid atmosphere, causing some of the reactive electrophilic groups in the reactive polymer particles to react with the reactive nucleophilic groups in said fibers.

[0120] The method of the present invention preferably includes sterilization of the hemostatic sheet. The hemostatic sheet may be sterilized prior to sterile packaging. Alternatively, the sheet may be sterilized within the sealed packaging.

[0121] The present invention is further illustrated by the following non-limiting examples. EXAMPLES

[0122] Generally, whenever the residual moisture content after drying (in the dry powder, granulation and / or cohesive fibrous carrier structure) is not specified, the level will be below 2.0% w / w.

[0123] (Preparation of NHS-POx) NHS side chain activated poly[2-(ethyl / hydroxy-ethyl-amido-ethyl / NHS-ester-ethyl-ester-ethyl-amido-ethyl)-2-oxazoline] terpolymer containing 20% ​​NHS ester groups (=EL-POx, 20% NHS) was synthesized as follows: Poly[2-(ethyl / methoxy-carbonyl-ethyl)-2-oxazoline] copolymer (DP=+ / -100) was synthesized by CROP using 60% 2-ethyl-2-oxazoline (EtOx) and 40% 2-methoxycarbonyl-ethyl-2-oxazoline (MestOx). 1 H-NMR) was used to obtain statistical copolymers containing Second, a polymer containing 40% 2-methoxycarbonyl-ethyl groups was reacted with ethanolamine to give 40% 2-hydroxy-ethyl-amido-ethyl groups ( 1 H-NMR) was then used to obtain a copolymer with half of the 2-hydroxy-ethyl-amido-ethyl groups reacted with succinic anhydride,1 A terpolymer was obtained with 60% 2-ethyl groups, 20% 2-hydroxy-ethyl-amido-ethyl groups and 20% 2-carboxy-ethyl-ester-ethyl-amido-ethyl groups by H-NMR. Finally, the 2-carboxy-ethyl-ester-ethyl-amido-ethyl group was activated by N-hydroxysuccinimide (NHS) and diisopropylcarbodiimide (DIC) to give EL-POx, 20% NHS. 1 According to H-NMR, NHS-POx contained 20% NHS-ester groups. NHS-POx was dissolved in water between 2 and 8 °C (60 g in 300 mL) and lyophilized by cooling at minus 80 °C for 30 min. The lyophilized powder so obtained was dried in a Rotavap at 40 °C until the moisture content was less than 0.8% w / w as determined by Karl Fischer titration. This dry (white) powder was ground using a ball mill (Retch MM400) to an average particle size of ≤40 μm (D[4,3]) and vacuum sealed in alu-alu bags.

[0124] (Staining of NHS-POx powder) 20 g of NHS-POx powder was dissolved in water and mixed with 50 mg of Brilliant Blue FCF (Sigma Aldrich) using a high-speed disperser (Ultra-Turrax, IKA). Immediately after mixing (2 min), the solution was frozen at -78 °C and then freeze-dried overnight. The so-obtained freeze-dried powder was dried in a Rotavap at 40 °C until the residual moisture content was less than 0.8% w / w as determined by Karl Fischer titration. The dry (blue) powder was then ground using a ball mill (Retch MM400) to a blue-stained NHS-POx powder with an average particle size of 40 μm or less (D[4,3]) and vacuum-sealed in an alu-alu bag.

[0125] (Preparation of NU-POx) Polyoxazolines containing ethyl and amine groups in the alkyl side chains were synthesized by CROP of EtOx and MestOx followed by amidation of the methyl ester side chains with ethylenediamine to give poly(2-ethyl / aminoethylamidoethyl-2-oxazoline) copolymers (NU-POx). 1 By H-NMR, NU-POx contained 10% NH2. NU-POx was dissolved in water between 2 and 8 °C (60 g in 300 mL) and freeze-dried by cooling at -80 °C for 30 min. The freeze-dried powder so obtained was dried in a Rotavap at 40 °C until the moisture content was less than 0.8% w / w as determined by Karl Fischer titration. The dried powder was ground in a benchtop grinder until the average particle size was less than 100 μm (D[4,3]) and vacuum sealed in alu-alu bags.

[0126] (Preparation of reactive NHS-POx / P188 granules) P188 coated reactive NHS-POx granules containing 1.5, 2.5 or 3.5 wt.% Pluronic P188 were prepared by heating NHS-POx with P188 powder in a high shear mixer at 65°C for 10 min and then cooling to ambient conditions. The coated granules were milled using a ball mill (Retch MM400) to an average particle size of 40 μm or less (D[4,3]) and vacuum sealed in alu-alu bags.

[0127] The particle size distribution of the granules thus obtained was approximately 90 vol.% < 80 μm, 50 vol.% < 40 μm, and 10 vol.% < 10 μm.

[0128] 1 The NHS-POx / P188 (2.5%) granules were analyzed using H-NMR spectroscopy. 15 mg of the granules were dissolved in 1 mL of dimethyl sulfoxide (DMSO-d6). The solution was transferred to an NMR tube and 1H-NMR spectrum was recorded. From the spectrum obtained, the amount of NHS bound to NHS-POx can be calculated. The amount of NHS bound to NHS-POx in the granulation was calculated to be 101 percent compared to the NHS-POx starting material, indicating that no degradation or cross-linking occurs during granulation.

[0129] The NHS-POx / P188 granules were further analyzed by size exclusion chromatography. 5 mg of granules were dissolved in 2.50 mL of N,N-dimethylacetamide containing 50 mM lithium chloride, the eluent for the SEC analysis. The SEC was measured against poly(methyl methacrylate) standards, and the M n , M w and PDI were determined. The PDI was less than 1.5, indicating that no cross-linking occurred during granulation.

[0130] Preparation of reactive NHS-POx / carbonate granules A 1:1 mole / mole mixture of sodium carbonate and sodium bicarbonate was prepared by dissolving 25.31 grams of sodium carbonate and 20.06 grams of sodium bicarbonate in 350 mL of ultrapure water, followed by flash freezing in liquid nitrogen and lyophilization. The resulting powder was dried under reduced pressure and vacuum sealed in an alu-alu bag.

[0131] 25.28 grams of NHS-POx was mixed with 1.75 grams of sodium carbonate / sodium bicarbonate mixture and 0.80 mL of isopropyl alcohol (IPA) using a high shear mixer until a homogenous powder was obtained.

[0132] After mixing, the wet granulation was dried under vacuum until the IPA content was less than 0.1% w / w. The dried granulation was ground in a coffee grinder until the average particle size was less than 25 μm and vacuum sealed in alu-alu bags.

[0133] (Preparation of reactive NHS-POx / P188 / carbonate granules) P188 coated reactive NHS-POx / carbonate granules containing 1.5, 2.5 or 3.5 wt.% Pluronic P188 were prepared by heating the NHS-POx / carbonate granules with P188 powder in a high shear mixer at 65°C for 10 min and then cooling to ambient conditions. The coated granules were milled using a ball mill (Retch MM400) to an average particle size of 40 μm or less (D[4,3]) and vacuum sealed in alu-alu bags.

[0134] The particle size distribution of the granules thus obtained was approximately 90 vol.% < 20 μm, 70 vol.% < 10 μm and 40 vol.% < 5 μm.

[0135] (Preparation of reactive NHS-POx / NU-POx granules (IPA granulation)) Blue or white (undyed) NHS-POx powder was wetted with isopropyl alcohol (IPA) in a high shear mixer until a homogenous snow-like powder containing approximately 1-2% w / w IPA was obtained. After this, NU-POx powder was added and mixed. The wetted blue NHS-POx powder was mixed with NU-POx powder in a molar ratio of 1:0.6, the molar ratio referring to the ratio of the number of NHS groups provided by NHS-POx to the number of amine groups provided by NU-POx. The wetted undyed NHS-POx powder was also mixed with NU-POx powder in other molar ratios (1:0.8; 1:1 and 1:1.2).

[0136] After mixing, 1 The wet granulation was dried under reduced pressure until the IPA content was less than 0.1% w / w as determined by H-NMR. The dried granulation was milled using a ball mill (Retch MM400) to an average particle size of 50 μm or less (D[4,3]) and vacuum sealed in alu-alu bags.

[0137] The particle size distribution of the granules thus obtained was approximately 90 vol.% < 90 μm, 50 vol.% < 45 μm and 10 vol.% < 15 μm.

[0138] 1 The NHS-POX / NU-POx granules (1:1) were analyzed using H-NMR spectroscopy. 25 mg of granules were dissolved in trifluoroacetic acid (0.20 mL) by sonication for 20 min. After complete dissolution of the granules, the sample was diluted with deuterated dimethyl sulfoxide (DMSO-d6) (0.80 mL) containing maleic acid (2.5 mg / mL) as an internal standard and transferred to an NMR tube. 1 H-NMR spectra were recorded. From the spectra obtained, the amount of NHS bound to NHS-POx can be calculated, along with the molar ratio of NHS and amine groups present in the granulate. The amount of NHS bound to NHS-POx in the granulate is comparable to the amount of NHS bound to the NHS-POx starting material, indicating that no collapse or cross-linking occurs during granulation.

[0139] Total polymer recovery in the NMR samples, i.e., the combination of NHS-POx and NU-POx, was determined using known amounts of an internal standard (maleic acid) and recorded NMR spectra of different concentrations of NHS-POx and NU-POx. 1 The total polymer recovery was determined using a calibration curve generated from the H-NMR spectrum and was determined to be 99 percent, indicating that no insoluble crosslinked material was formed.

[0140] The NHS-POX / NU-POx granules (1:1) were further analyzed by size exclusion chromatography. 20 mg of the granules were treated with acetic anhydride (1.00 mL) at 50° C. for 1 h. Methanol (2.00 mL) was then added and the mixture was stirred at 50° C. for an additional 1 h. An aliquot (0.75 mL) was taken and all volatiles were removed under reduced pressure. The sample was dissolved in N,N-dimethylacetamide (2.50 mL) containing 50 mM lithium chloride, the eluent for SEC analysis. SEC was measured against poly(methyl methacrylate) standards and the M was calculated from the resulting size exclusion chromatogram. n , M wand PDI were determined. The PDI was below 1.5, indicating that no cross-linking occurred during granulation. Analytical validation of this size exclusion chromatography method showed that intentional cross-linking of NHS-POx and NU-POx at a level of 0.05 mol% increased the PDI to above 2.5.

[0141] (Preparation of reactive NHS-POx / NU-POx granules (acetone granulation)) Blue or white (undyed) NHS-POx powder was wetted with acetone in a high shear mixer until a homogenous snow-like powder containing approximately 1-2% w / w acetone was obtained. After this, NU-POx powder was added and mixed. The wetted blue NHS-POx powder was mixed with NU-POx powder in a molar ratio of 1:0.20, the molar ratio referring to the ratio of the number of NHS groups provided by NHS-POx to the number of amine groups provided by NU-POx. The wetted undyed NHS-POx powder was also mixed with NU-POx powder in other molar ratios (1:0.10 and 1:0.40).

[0142] After mixing, 1 The wet granulation was dried under reduced pressure until the acetone content was less than 0.1% w / w as determined by H-NMR. The dried granulation was milled using an Ultra Centrifugal Mill (Retch ZM200) and sieved through a test sieve with a mesh size of 63 μm. The granulation fraction that passed through the sieve was collected and had an average particle size of 50 μm or less (D[4,3]). The granulation was vacuum sealed in an alu-alu bag.

[0143] The particle size distribution of the granules thus obtained was approximately 90 vol.% < 90 μm, 50 vol.% < 45 μm and 10 vol.% < 15 μm.

[0144] 1The NHS-POX / NU-POx granules (1:0.20) were analyzed using H-NMR spectroscopy. 25 mg of granules were dissolved in trifluoroacetic acid (0.20 mL) by sonication for 20 min. After complete dissolution of the granules, the sample was diluted with deuterated dimethylsulfoxide (DMSO-d6) (0.80 mL) containing maleic acid (2.5 mg / mL) as an internal standard and transferred to an NMR tube. 1 H-NMR spectra were recorded. From the spectra obtained, the amount of NHS bound to NHS-POx can be calculated, along with the molar ratio of NHS and amine groups present in the granulate. The amount of NHS bound to NHS-POx in the granulate is comparable to the amount of NHS bound to the NHS-POx starting material, indicating that no collapse or cross-linking occurs during granulation.

[0145] Total polymer recovery in the NMR samples, i.e., the combination of NHS-POx and NU-POx, was determined using known amounts of an internal standard (maleic acid) and recorded NMR spectra of different concentrations of NHS-POx and NU-POx. 1 The total polymer recovery was determined using a calibration curve generated from the H-NMR spectrum and was determined to be 99 percent, indicating that no insoluble crosslinked material was formed.

[0146] The NHS-POX / NU-POx granules (1:0.20) were further analyzed by size exclusion chromatography. 20 mg of the granules were treated with acetic anhydride (1.00 mL) at 50° C. for 1 h. Methanol (2.00 mL) was then added and the mixture was stirred at 50° C. for an additional 1 h. An aliquot (0.75 mL) was taken and all volatiles were removed under reduced pressure. The sample was dissolved in N,N-dimethylacetamide (2.50 mL) containing 50 mM lithium chloride, the eluent for SEC analysis. SEC was measured against poly(methyl methacrylate) standards and the M was determined from the resulting size exclusion chromatogram. n , M w and PDI were determined. The PDI was less than 1.5, indicating that no cross-linking occurred during granulation.

[0147] (Preparation of reactive NHS-POx / NU-POx / P188 granules) Reactive NHS-POx / NU-POx granules were prepared as described above. Reactive NHS-POx / NU-POx granules coated with 2.5% w / w P188 were then prepared by heating the NHS-POx / NU-POx granules with P188 powder in a high shear mixer at 65°C for 10 min and then cooling to ambient conditions. The coated granules were milled using a ball mill (Retch MM400) to an average particle size of 40 μm or less (D[4,3]) and vacuum sealed in alu-alu bags.

[0148] The particle size distribution of the granules thus obtained was approximately 90 vol.% < 80 μm, 50 vol.% < 40 μm, and 10 vol.% < 10 μm.

[0149] 1 The NHS-POx / NU-POx / P188 granules were analyzed using H-NMR spectroscopy. 25 mg of powder was dissolved in trifluoroacetic acid (0.20 mL) by sonication for 20 min. After complete dissolution of the granules, the sample was diluted with deuterated dimethyl sulfoxide (DMSO-d6) (0.80 mL) and transferred to an NMR tube. 1 H-NMR spectrum was recorded, from which the amount of unreacted NHS was calculated to be 98 percent compared to NHS-POx.

[0150] The NHS-POx / NU-POx / P188 granules were further analyzed by size exclusion chromatography. 20 mg of granules were treated with acetic anhydride (1.00 mL) at 50° C. for 1 h. Methanol (2.00 mL) was then added and the mixture was stirred at 50° C. for an additional 1 h. An aliquot (0.75 mL) was taken and all volatiles were removed under reduced pressure. The sample was dissolved in N,N-dimethylacetamide (2.50 mL) containing 50 mM lithium chloride, the eluent for SEC analysis. SEC was measured against poly(methyl methacrylate) standards and the M was calculated from the resulting size exclusion chromatogram. n , M wand PDI were determined. The PDI was less than 1.5, indicating that no cross-linking occurred during granulation.

[0151] (Preparation of reduced cross-linked gelatin (RXL)) Reduced cross-linked gelatin (RXL) was prepared by two procedures: 12 grams of gelatin powder (Gelita-SPON®, Gelita Medical GmbH) was dissolved in 350 mL of 0.1 molar aqueous sodium hydroxide solution by stirring at 40° C. for 2 hours. After obtaining a clear solution, the mixture was cooled to ambient temperature and the pH was adjusted to 7 by adding 32.5 mL of 1.0 molar aqueous hydrochloric acid solution. The solution was flash frozen using liquid nitrogen and freeze-dried overnight. The powder was then ground in a coffee grinder, dried under reduced pressure and vacuum-sealed in an alu-alu bag. Hereafter, this reduced cross-linked gelatin is referred to as RXL-LS (low salt). 12 grams of gelatin powder (Gelita-SPON®, Gelita Medical GmbH) was dissolved in 360 mL of 1.0 molar aqueous sodium hydroxide solution by stirring for 10 minutes at 40° C. The resulting clear solution was cooled to ambient temperature and the pH was reduced to 7 by adding 30 mL of concentrated hydrochloric acid solution (37% w / w). The solution was flash frozen using liquid nitrogen and freeze-dried overnight. The powder was then ground in a coffee grinder, dried under reduced pressure, and vacuum-sealed in an alu-alu bag. Hereafter, this reduced cross-linked gelatin is referred to as RXL-HS (high salt).

[0152] (Preparation of reactive NHS-POx / RXL granules (low and high salt)) Reactive NHS-POx / RXL granules were prepared as follows: 5 g of blue NHS-POx powder was wetted with IPA in a high shear mixer until a homogenous snow-like powder containing approximately 1-2% w / w IPA was obtained. After this, 5 g of RXL-LS or RXL-HS powder was added and mixed. After mixing, 1The wet granulation was dried under reduced pressure until the IPA content was less than 0.1% w / w as determined by H-NMR. The dried granulation was ground in a coffee grinder to an average particle size of 90 μm or less (D[4,3]) and vacuum sealed in alu-alu bags.

[0153] The particle size distribution of the granules thus obtained was approximately 90 vol.% < 190 μm, 50 vol.% < 60 μm and 10 vol.% < 15 μm.

[0154] Granules containing RXL 1 The dispersion was analyzed by H-NMR spectroscopy. For this purpose, 1.0 mL of deuterated chloroform (CDCl3) containing 5% (v / v) acetic acid was added to 25 mg of the granulation. The NHS-POx was selectively extracted by ultrasonicating the sample for 20 min. The dispersion was passed through a 0.22 μm filter and transferred to an NMR tube. 1 H-NMR spectrum was recorded, from which the amount of unreacted NHS was calculated to be 98 percent compared to NHS-POx.

[0155] The recovery of NHS-POx in the NMR samples was evaluated using trimethylsilane as an internal standard as well as different concentrations of NHS-POx. 1 The total NHS-POx recovery was determined using a calibration curve generated from H-NMR spectra. The total NHS-POx recovery was determined to be 100 percent, indicating that no insoluble cross-linked material was formed.

[0156] The NHS-POx / RXL granulations were further analyzed by size exclusion chromatography. 1 An aliquot (0.15 mL) was removed from the solution used for H-NMR spectroscopy. This solution was diluted with N,N-dimethylacetamide (1.00 mL) containing 50 mM lithium chloride, the eluent for the SEC analysis. The SEC was run against poly(methyl methacrylate) standards, and the M n , M wand PDI was determined. The PDI was below 1.5, again indicating that no cross-linking occurred during granulation.

[0157] Preparation of Reactive NHS-POx / RXL Granules Containing Carbonate First, a 1:1 mole / mole mixture of sodium carbonate and sodium bicarbonate was prepared by dissolving 25.31 g of sodium carbonate and 20.06 g of sodium bicarbonate in 350 mL of ultrapure water. The solution was flash frozen in liquid nitrogen and lyophilized. The resulting powder was dried under reduced pressure and vacuum sealed in an alu-alu bag.

[0158] NHS-POx / RXL / carbonate granules were prepared as follows: 5g of RXL-LS or RXL-HS was mixed with 0.178g of sodium carbonate / bicarbonate using a high shear mixer. 5g of blue NHS-POx containing approximately 1-2% w / w IPA was then added and mixed until a homogenous powder was obtained. After mixing, 1 The wet granulation was dried under reduced pressure until the IPA content was less than 0.1% w / w as determined by H-NMR. The dried granulation was ground in a coffee grinder to an average particle size of 100 μm or less (D[4,3]) and vacuum sealed in alu-alu bags.

[0159] (Preparation of reactive NHS-POx / NH2-PEG granules) NHS-POx (6.9 g) was wetted with IPA in a high shear mixer until a homogenous snow-like powder containing about 1-2% w / w IPA was obtained, followed by the addition of 8.1 g of Amine-PEG-amine, 2-arm, MW2k (ex-Creative PEGWorks) (molar ratio 1:1.16, the molar ratio referring to the ratio of the number of NHS groups provided by NHS-POx to the number of amine groups provided by PEG-amine). 1 The formed granulation was dried under reduced pressure until the IPA content was less than 0.1% w / w as determined by H-NMR. The dried granulation was ground in a coffee grinder to an average particle size of 100 μm or less (D[4,3]) and vacuum sealed in alu-alu bags.

[0160] 1 The NHS-POX / NH2-PEG granules were analyzed using H-NMR spectroscopy. 25 mg of granules were dissolved in trifluoroacetic acid (0.20 mL) by sonication for 20 min. After complete dissolution of the granules, the sample was diluted with deuterated dimethyl sulfoxide (DMSO-d6) (0.80 mL) and transferred to an NMR tube. 1 H-NMR spectrum was recorded, from which the amount of unreacted NHS was calculated to be 97 percent compared to NHS-POx.

[0161] The NHS-POX / NH2-PEG granules were further analyzed by size exclusion chromatography. 20 mg of the granules were treated with acetic anhydride (1.00 mL) at 50° C. for 1 h. Methanol (2.00 mL) was then added and the mixture was stirred at 50° C. for an additional 1 h. An aliquot (0.75 mL) was taken and all volatiles were removed under reduced pressure.

[0162] The samples were dissolved in N,N-dimethylacetamide (2.50 mL) containing 50 mM lithium chloride, the eluent for SEC analysis. SEC was measured against poly(methyl methacrylate) standards, and the M n , M w and PDI were determined. The PDI was less than 1.5, indicating that no cross-linking occurred during granulation.

[0163] (Preparation of reactive NHS-PEG / NU-POx granules) 1.07 grams of NHS-PEG 4-arm MW10k (formerly Creative PEGWorks) and 0.46 grams of NU-POx were thoroughly mixed with 50 μL of diethyl ether using a pestle and mortar. After formation of a homogenous mixture, it was dried under reduced pressure and vacuum sealed in an alu-alu bag.

[0164] (Preparation of reactive NHS-POx / Gelita Spon granules) 7.01 g of pre-dried gelatin powder (Gelita-SPON®, formerly Gelita Medical GmbH) with a moisture content of less than 0.2% w / w was dispersed in dichloromethane (200 mL) using a high shear mixer operating at 20,000 rpm for 20 min. NHS-POx (7.02 g) was then added and stirring was continued for 5 min. NHS-POx did not dissolve. All volatiles were removed from the suspension under reduced pressure. The resulting powder was ground using a coffee grinder until the average particle size was ≤95 μm (D[4,3]), vacuum sealed in an alu-alu bag, further dried under reduced pressure and vacuum sealed in an alu-alu bag.

[0165] The particle size distribution of the granules thus obtained was approximately 90 vol.% < 190 μm, 50 vol.% < 80 μm and 10 vol.% < 15 μm.

[0166] Granulated material 1 The NHS-POx were analyzed by H-NMR spectroscopy. For this purpose, 1.0 mL of deuterated chloroform (CDCl3) containing 5% (v / v) acetic acid was added to 25 mg of the granulation. The NHS-POx were selectively extracted by ultrasonicating the sample for 20 min. The dispersion was passed through a 0.22 μm filter and transferred to an NMR tube. 1 H-NMR spectrum was recorded, from which the amount of unreacted NHS was calculated to be 97 percent compared to NHS-POx.

[0167] The granulation was further analyzed by size exclusion chromatography (SEC) analysis. An aliquot (0.15 mL) of the filtered NHS-POx extract described above was diluted with N,N-dimethylacetamide (1.00 mL) containing 50 mM lithium chloride, the eluent for SEC analysis.

[0168] The sample was analyzed by SEC against a poly(methyl methacrylate) standard and had a PDI of 1.45, indicating that no crosslinking had occurred.

[0169] (Adhesive fibrous carrier structure) The following commercially available hemostatic products were selected for use as fibrous carrier structures in the preparation of tissue adhesive sheets according to the present invention: Gelita Tuft-It®: A cohesive fibrous carrier structure consisting of eight layers of reduced cross-linked gelfoam fibers. The eight layers, each about 2 mm thick, have dimensions of 50 mm x 75 mm. The moisture content of Gelita Tuft-It® is 15% or less. The product was dried in a vacuum oven at 40°C for several hours to reduce the moisture content to 2.0% w / w or less (determined by gravimetry) before impregnating the agglomerated particles.

[0170] (Bleeding experiment) Hemostatic efficacy was assessed using standardized ex-vivo and in-vivo porcine bleeding models. All models used heparin to prolong clotting times, increasing the activated clotting time (ACT) by approximately 2-3 fold.

[0171] Ex-vivo model: A live ex-vivo porcine model with a fresh liver perfused with fresh heparinized blood from the slaughterhouse to mimic the actual in-vivo environment as closely as possible. The liver is attached to a perfusion machine that maintains oxygenation, blood pH, temperature and blood pressure within the biologic boundaries. Two livers and 10 liters of heparinized blood (5000 units / L) are collected at the slaughterhouse. The livers are shipped on ice and the blood at ambient temperature. Within 2 hours of collection, the liver is inspected for lesions and closed with gloves and cyanoacrylate glue. Perfusion parameters: flow rate 600 ml / min, pressure 10-12 mmHg, temperature 37°C (+ / - 1°C), carbogen 0.25 liters per minute. A circular bleeding wound (8 mm diameter) is created on the liver surface using a flat round rotary scraping tool, with a rubber onlay so that the depth of the punched bleeding area is always 3 mm. Once the liver is properly perfused (check color and temperature), test the sample according to the following procedure: cut the sample to the appropriate size (2.7 x 2.7 cm); turn on the camera; check the number of sites with the camera; punch an 8 mm biopsy; cut and remove the biopsy; remove blood from the bleeding site with gauze (2x); collect blood with pre-weighed gauze for 30 seconds; score bleeding (by two investigators); The specimen is placed over the bleeding area with pre-moistened gauze (saline) and held with slight pressure for 1 minute; observed for 5 minutes (check and score for adhesion and hemostasis) and repeated after 30 minutes.

[0172] In vivo model: A standardized combined penetrating splenic rupture is induced in anesthetized pigs (domestic pig, male, weight range: 40 kg, adult). A midline laparotomy is performed to access the spleen and other organs. A scalpel is used to create n=3 (S1...S3) subcapsular standardized lesions (10 mm x 10 mm). The hemostatic product is applied with gentle pressure by pre-moistened gauze (saline) and held down for 1 min. After product application, the time to hemostasis (TTH) is assessed. A TTH equal to zero means that hemostasis is already achieved after 1 min of pressure.

[0173] Patch scoring system: Clotting ++++ Achieved immediately after tamponade +++ Achieved <10 seconds after tamponade ++ Achieved <30 seconds after tamponade + Achieved within 3 minutes of tamponade Achieved after + / - 3 minutes, apply second tamponade - Not achieved

[0174] Patch scoring system: 10 minutes after application ++++ Very strong adhesion (patch breaks upon removal) +++ Strong adhesion (patch breaks when removed) ++ Strong adhesion (patch can be removed without damage) + Moderate adhesion (patch can be removed without damage) + / - Mild adhesion (patch can be removed without damage) - Not achieved

[0175] [Example 1] Impregnation of the carrier structure with dyed polymer particles A Vibratory Sieve Shaker AS 300 (Retsch) was operated for two consecutive periods of 5 min each to introduce the dyed NHS-POx powder into the different carrier structures. After preparation, the hemostatic patches were loaded into alu-alu pouches containing 1 g of silica and vacuum sealed.

[0176] Using the shaker described above, the blue NHS-POx powder was introduced into three different support structures: Gelatin foam (Gelita Rapid®, Gelita Medical Germany), sponge Collagen foam (Surgicoll®, MBP, Germany), sponge Fibrous carrier structures (Gelita Tuft-It®, Gelita Medical Germany) After the shaking process, the blue NHS-POx powder was found to have barely penetrated into the gelatin or collagen foams. When the foams were cut with a scalpel, it was evident that no deep impregnation had occurred.

[0177] In contrast, the shaking treatment resulted in the blue NHS-POx powder being homogeneously dispersed throughout the fibrous support structure.

[0178] [Example 2] [Impregnation of reactive polymer particles and granules into carrier structure] The Gelita Tuft-It® (approximately 0.71 grams) was impregnated with the NHS-POx powder and the NHS-POx / NU-POx (1:0.6) granulation, respectively, by a mechanical shaking process. The dye powder (approximately 0.75 grams) was introduced into the patch using a paint shaker (VIBA PRO V from Collomix GmbH). The holder of the array containing the carrier structure was clamped to the machine. The array was vibrated vertically.

[0179] The impregnated samples were placed on a PMMA plate and placed in an oven, where the samples were subjected to different heat treatments. To evaluate the powder adhesion, the samples were moved twice on the white PMMA plate. The results were considered as stuck if no blue powder was released. The results are shown in Table 1.

[0180] [Table 1]

[0181] No difference in adhesion results was observed between samples impregnated with NHS-POx powder and NHS-POx / NU-POx granules.

[0182] Both reactive NHS-POx powders and NHS-POx / NU-POx granules are hygroscopic. They can be reproducibly impregnated into fibrous support structures within 30 minutes of exposure at ambient temperature and below 40% relative humidity (RH). However, when impregnation is performed at, for example, 75% RH and 25° C., the particles / granules become sticky within minutes, resulting in non-reproducible and inhomogeneous impregnation characteristics.

[0183] [Example 3] A hemostatic patch (Gelita Tuft-It®; 50×75 mm, approximately 0.7 grams) was impregnated with 1 g of blue NHS-POx by shaking the patch on a sprung suspension driven by a "rattle" type air agitation engine. The engine was a NTP25B+C (Netter Vibration GmbH) operated at 6 bar, 146 Hz and a centrifugal force of 830 N. Ten cycles of 10 seconds each were used to disperse the dyed NHS-POx powder. After formation, the hemostatic patch was loaded into an alu-alu pouch containing 1 g of silica and vacuum sealed.

[0184] The patches were cut into 2 cm x 2 cm pieces and tested in triplicate in an ex vivo liver perfusion model. The time to hemostasis (TTH) was 0 min (after 1 min of compression) and no rebleeding was observed during the 30 min observation period. The patches showed very good adhesive properties. It was not possible to remove the patch without breaking it into pieces. In addition, the patches were found to have high flexibility and bending properties.

[0185] Furthermore, the patch was evaluated in an in vivo porcine heparinized model. The patch was found to exhibit high hemostatic efficacy and to have excellent adhesive properties. Active bleeding was efficiently stopped in the resection of various organs: spleen, liver and kidney. A summary of the ex-vivo and in-vivo results is shown in Table 2.

[0186] [Table 2]

[0187] [Example 4] A hemostatic patch (Gelita Tuft-It®; 50×75 mm, approximately 0.71 grams) was impregnated with reactive NHS-POx / NU-POx (1:0.6) granulation as described above. One gram of the granulation was distributed throughout the patch as described in Example 3. The hemostatic patch was then loaded into an alu-alu pouch containing 1 g of silica and vacuum sealed.

[0188] The patches were cut into 2 cm x 2 cm pieces and tested in triplicate in an ex vivo liver perfusion model. The time to hemostasis (TTH) was 0 (after 1 min of compression) and no rebleeding was observed during the 30 min observation period. The patches were also found to have high flexibility and bending properties.

[0189] Furthermore, the patch was evaluated in an in vivo porcine heparinization model. The patch was found to have very good clotting and adhesion properties. Active bleeding was efficiently stopped in the resection of different organs: spleen, liver and kidney. A summary of the results is shown in Table 3.

[0190] [Table 3]

[0191] [Example 5] Gelita Tuft-It® (50×75 mm, approximately 0.7 g) was impregnated with different reactive polymer powders. The hemostatic properties of the so obtained patches were tested in ex-vivo and in-vivo porcine bleeding models as previously described herein.

[0192] A pneumatic shaking device was used to impregnate the fibrous carrier structure with 1.4 g of powder. The fibrous carrier sheet was vibrated vertically. A long stroke engine (NTK 25 AL L, ex Netter Vibration GmbH) was operated at 6 bar, 11 Hz and an amplitude of 30 mm. Four cycles of 15 seconds were used to disperse the powder on the sheet. The granulation was distributed over the entire thickness of the sheet. The distribution over the entire surface of the sheet was also homogenous.

[0193] Nine different reactive polymer powders were tested. These powders contained water-soluble polymers bearing reactive electrophilic groups in the form of NHS-POx or in the form of pentaerythritol poly(ethylene glycol) ether tetrasuccinimidyl glutarate (NHS-PEG) of the former NOF America corporation. Some of the reactive polymer powders were granules containing, in addition to NHS-POx or NHS-PEG, a polymer bearing reactive nucleophilic groups capable of reacting with the reactive NHS groups of NHS-POx and NHS-PEG. The preparation of these granules has been described previously herein.

[0194] The granulations tested are listed below: NHS-POx / P188 NHS-POx / carbonate NHS-POx / Jerita Spon NHS-POx / NH2-PEG NHS-POx / RXL (high salt) NHS-POx / RXL (low salinity) Carbonate-containing NHS-POx / RXL (high salinity) NHS-PEG / RXL (low salt) NHS-PEG / NU-POx The different combinations of fibrous support structures and reactive polymer powders that were tested are shown in Table 4.

[0195] [Table 4]

[0196] The results obtained with these patches in ex-vivo and in-vivo porcine bleeding models are summarized in Table 5.

[0197] [Table 5]

[0198] [Example 6] A hemostatic patch (Gelita Tuft-It®; 50×75 mm, approximately 0.7 g) was impregnated with NHS-POx / NU-POx / P188 2.5%. One gram of granulation was distributed throughout the patch as described in Example 2. The hemostatic patch was then loaded into an alu-alu pouch containing 1 g of silica and vacuum sealed.

[0199] The patch was evaluated in an in vivo porcine heparinization model. The patch was found to have very good clotting and sufficient adhesive properties. The reduced adhesive properties allowed the patch to be removed in one piece, in contrast to an identical patch without P188. Active bleeding was efficiently stopped in the resection of various organs: spleen, liver and kidney. A summary of the results is shown in Table 6.

[0200] [Table 6]

[0201] [Example 7] Hemostatic patches (Gelita Tuft-It®; 50×75 mm, approximately 0.7 g) were impregnated with NHS-POx / NU-POx or NHS-POx / NU-POx / P188 containing 1.5%, 2.5% or 3.5% Pluronic P188, respectively. One gram of granulation was distributed throughout the patch as described in Example 2. The hemostatic patches were then loaded into alu-alu pouches containing 1 g of silica and vacuum sealed.

[0202] The patches were evaluated in an in vivo porcine heparinized model with splenectomy (arterial bleeding) and the results are summarized in Table 7.

[0203] [Table 7]

[0204] Patches containing NHS-POx / NU-POx / P188 were easier to remove "in one piece" after application than patches containing NHS-POx / NU-POx.

[0205] [Example 8] Experiments were conducted to determine the effect of NU-POx content of reactive NHS-POx / NU-POx granulations on the in-vivo performance of hemostatic patches.

[0206] (Impregnation method) Hemostatic patches (Gelita Tuft-It®; 50×75 mm, approximately 0.7 g) were impregnated with reactive NHS-POx / NU-POx granules prepared by acetone granulation in molar ratios of 1:0.10, 1:0.20, and 1:0.40, the molar ratio referring to the ratio of the number of NHS groups provided by NHS-POx to the number of amine groups provided by NU-POx. The same hemostatic patches were also impregnated with reactive NHS-POx powder.

[0207] Using a Fibroline SL-Preg lab machine, 1 gram of granulation / powder was distributed throughout the patch. The hemostatic patch was then cemented, dried, loaded into an alu-alu pouch containing 1 gram of silica, and vacuum sealed.

[0208] machine The Fibroline SL-Preg laboratory machine moves particles between electrodes by applying voltages of up to 40 kV at frequencies of up to 200 Hz for periods of up to 60 seconds. The two electrode plates are approximately 50 x 40 cm in size. The upper plate is grounded.

[0209] The following standard settings were used: 40 kV, 100 Hz, 20 s.

[0210] array After attaching the 3D printed PMMA array to the lower electrode plate, the powder was poured into the array by gravity. A scraping carton or metal spatula was used to fill the array with reactive polymer powder. The array was 50 x 75 x 4 mm and contained 22 x 33 = 726 square wells (inner dimensions of each well: 2 x 2 x 2 mm). The total volume of the 726 wells was approximately 5.8 mL.

[0211] Spacer A spacer mask was placed on top of the array. The use of a spacer allows the particles to move up and down when subjected to an alternating electric field. If a spacer is not used, it limits penetration into and distribution through the carrier. In the case of the Tuft-IT this was a 3mm mask. This gives an electrode distance of 3+4mm=7mm.

[0212] The in vivo performance of hemostatic patches containing NHS-POx:NU-POx granules (0, 10, 20 and 40 percent of amine groups from NU-POx, percentages calculated based on the number of NHS groups provided by NHS-POx) or NHS-POx powder was evaluated in a non-heparinized in-vivo porcine model. Details of the tested patches are shown in Table 8.

[0213] [Table 8]

[0214] (In vivo test) Studies were performed on adult female domestic pigs (40-50 kg). No anticoagulant was applied. Patch performance was tested on both the spleen and liver. The spleen or liver were located and exposed as necessary over the course of the study period, and their natural moisture was maintained by covering them with saline-soaked sponges.

[0215] Different types of damage created: Liver: abrasion, biopsy punch and excision wound Spleen: resection wound

[0216] Appropriately sized portions of liver parenchyma were abraded / punched to induce moderate to severe bleeding. Liver abrasions were made with a scalpel and a 1x1 cm2 template, and circular punches were made using an 8 mm circular biopsy punch. Liver and spleen resection wounds were made using a surgical knife.

[0217] Patches were applied immediately after tissue excision or scarification: Biopsy punch and 2 x 2 cm pieces for scraping Complete 7.5 x 5 cm patch for excision wound

[0218] The test patch was applied to the bleeding tissue and gently pressed by applying pressure using gauze pre-moistened with saline solution. Tamponade was applied initially for a 10 second period, followed by a 30 second interval, up to a total of 5 minutes.

[0219] An unimpregnated Tuft-IT patch was used as a reference (referred to as Tuft-IT).

[0220] The results of the in vivo studies are summarized in Table 9.

[0221] [Table 9]

[0222] Patches 1-4 showed very strong tissue adhesion, whereas only mild adhesion was observed for the Tuft-IT patch.

[0223] Patches 1 and 2 showed very little swelling after application, while patches 3-4 showed more significant, but still acceptable, swelling.

[0224] Example 9 Hemostatic patches (Gelita Tuft-It®; 50×75 mm, approximately 0.7 g) were impregnated with either a solution of NHS-POx, NHS-POx powder, or NHS-POx / NU-POx granules. The NHS-POx / NU-POx granules used were made by acetone granulation at a molar ratio of 1:0.20 (see Example 8).

[0225] A spray solution containing NHS-POx was prepared by dissolving NHS-POx in a 1:1 mixture of isopropyl alcohol and dichloromethane (200 g / L). Using a laboratory glass sprayer and pressurized air, 5 mL of this spray solution was impregnated into the patches in one spray cycle. The total amount of NHS-POx delivered in this manner was 1 gram per patch. After impregnation, the patches were dried in an oven at 40° C. for 2 hours and then stored in a desiccator for 2 days before being loaded into an alu-alu pouch containing 1 g of silica and vacuum sealed.

[0226] Additionally, using the procedure described in Example 8, patches were impregnated with 1 gram of NHS-POx powder or 1 gram of NHS-POx / NU-POx granulation.

[0227] The performance of the so-prepared patches was tested in triplicate in an ex vivo liver perfusion model under mild (<20 mL / min) and severe bleeding (>50 mL / min) conditions. A circular bleeding wound (8 mm diameter) was created on the liver surface using a flat round rotary scraping tool, and a rubber onlay was used to ensure that the punched bleeding area always had a depth of 3 mm. The results are shown in Table 10.

[0228] [Table 10]

Claims

1. A biocompatible, flexible hemostatic sheet comprising: A water-resistant, adhesive fibrous support structure comprising three-dimensional interconnected void spaces, the water-resistant, adhesive fibrous support structure comprising fibers containing a nucleophilic polymer carrying reactive nucleophilic groups; and a plurality of reactive polymer particles distributed within the interstitial spaces, the reactive polymer particles comprising a water-soluble electrophilic polymer carrying at least three reactive electrophilic groups, the reactive electrophilic groups being capable of reacting with amine groups in tissues and blood and the reactive nucleophilic groups of the nucleophilic polymer under formation of covalent bonds, the reactive polymer particles having a diameter in the range of 0.5-100 μm and present in an amount of at least 3% by weight of the fibrous carrier structure; Including, the water-soluble electrophilic polymer is a polyoxazoline; A hemostatic sheet, wherein the reactive electrophilic group is a succinimidyl ester.

2. The hemostatic sheet according to claim 1, wherein the fibers of the fibrous carrier structure have an average diameter of 1 to 500 μm.

3. The hemostatic sheet according to claim 1 or 2, wherein the fibrous carrier structure is a felt structure, a woven structure or a knitted structure.

4. The hemostatic sheet according to any one of claims 1 to 3, wherein the reactive polymer particles contain at least 10 wt. % of the water-soluble electrophilic polymer.

5. The hemostatic sheet according to any one of claims 1 to 4, wherein the reactive polymer particles are particle aggregates comprising (i) electrophilic particles containing the water-soluble electrophilic polymer, and (ii) nucleophilic particles containing a nucleophilic crosslinking agent.

6. 6. The hemostatic sheet according to claim 5, wherein said electrophilic particles contain at least 30 wt. % of said water-soluble electrophilic polymer.

7. 7. The hemostatic sheet according to claim 5 or 6, wherein the nucleophilic particles contain at least 30 wt. % of the nucleophilic crosslinking agent.

8. The reactive polymer particles have the following composition: (a) 50-95 wt. % of said water-soluble electrophilic polymer bearing at least three of said reactive electrophilic groups; (b) 5 to 50 wt. % of said nucleophilic crosslinker; (c) 0 to 50 wt. % of a polysaccharide The hemostatic sheet according to any one of claims 5 to 7, wherein the combined combination of components (a) to (c) constitutes at least 80 wt. % of the reactive polymer particles.

9. The hemostatic sheet according to any one of claims 5 to 8, wherein the reactive polymer particles contain the water-soluble electrophilic polymer and the nucleophilic crosslinking agent in amounts such that the ratio between the total number of reactive electrophilic groups provided by the water-soluble electrophilic polymer and the total number of reactive nucleophilic groups provided by the nucleophilic crosslinking agent is in the range of 25:1 to 1:

1.

10. The hemostatic sheet according to any one of claims 1 to 9, wherein the nucleophilic polymer is selected from proteins, chitosan, synthetic polymers carrying reactive nucleophilic groups, carbohydrate polymers carrying reactive nucleophilic groups, and combinations thereof.

11. The hemostatic sheet according to claim 10, wherein the nucleophilic polymer is selected from gelatin, collagen, chitosan, and combinations thereof.

12. The hemostatic sheet according to claim 11 , wherein the nucleophilic polymer is gelatin.

13. The hemostatic sheet described in claim 11, wherein the nucleophilic polymer is cross-linked gelatin.

14. The hemostatic sheet according to any one of claims 1 to 13, wherein the fibrous carrier structure comprises at least 50 wt. % of the nucleophilic polymer.

15. 25-200mg / cm 3 The hemostatic sheet according to any one of claims 1 to 14, having an uncompressed density of

16. A sealed package containing one or more hemostatic sheets according to any one of claims 1 to 15.

17. 1. A method for preparing a hemostatic sheet, the method comprising: Providing a sheet of the water-resistant adhesive fibrous carrier structure according to any one of claims 1 to 3 and 10 to 14, Providing reactive polymer particles according to any one of claims 1 to 9; and distributing the reactive polymer particles within the interstitial spaces of the fibrous support structure. A method comprising:

18. 20. The method of claim 17, wherein the fibrous support structure containing the reactive polymer particles distributed therein is exposed to a humid atmosphere to react the reactive nucleophilic groups in the fibers with the reactive electrophilic groups in the reactive polymer particles.

Citation Information

Patent Citations

  • Nonwoven fabric

    JP2010520377A

  • Fibrous tissue sealant and method of use thereof

    JP2012509139A

  • Hemostatic sponge

    JP2013523296A

  • Electrophilically activated polyoxazoline-derived crosslinked polymers and implants

    JP2014503017A

  • hemostatic components

    JP2014533988A